Takeda meets targets during 2015 business year

Takeda has announced its financial results for the 2015 business year, during which it delivered a reported revenue total of 1.81 trillion yen (11.54 billion pounds).

This represented a year-on-year increase of 3.4 percent in terms of underlying growth, with a reported revenue growth rate of 1.7 percent. This was driven by the strong performance of the company's key growth drivers, including its gastrointestinal, oncology, central nervous system and emerging market businesses.

Takeda has designated 2016 to be a turnaround year for the company, with the 2015 performance meeting its management guidance for the second consecutive year. Its portfolio of growing products is helping to offset the impact of recent patent expiries.

In particular, therapies such as Entyvio, Ninlaro, Takecab, Brintellix, Adcetris, Azilva and Lotriga showed strong momentum.

For 2016, the company expects to achieve mid-single digit growth in terms of underlying revenue, with low-to-mid-teen growth in earnings.

Christophe Weber, president and chief executive officer of Takeda, said: "Takeda aims to relentlessly execute our strategic roadmap to deliver our long-term aspiration, and will serve the needs of the patients, with the best-in-class agility and innovation."